While measures implemented by CMS in 2017 stabilized the individual marketplace and improved performance of health insurance exchanges, those without federal subsidies have limited coverage options, according to the reports.
Three reports released by CMS provide an update on the current status of the federal and state-based health insurance exchanges and the individual health insurance markets. While measures implemented in 2017 stabilized the individual marketplace and improved performance of the exchanges, those without subsidies have limited coverage options, according to the reports.
The 3 reports are:
The reports focused on the following aspects of the exchanges:
The individual health insurance marketplace saw a decline in 23 states between 2015 and 2016, particularly among the unsubsidized individuals, with double-digit declines in 10 states. A big cause for concern is the disparity in reduction between subsidized versus unsubsidized enrollment seen for the 2017 plan year: a 3% drop versus a 20% drop, respectively. This drop coincided with a 21% growth in average monthly premiums.
In response to this troubling drop in the individual exchanges, CMS utilized and expanded the role of private brokers and insurance agents who were documented to have assisted with 3,660,668 health plan enrollments and 42% of 2018 plan open enrollments on the federal exchanges. This was a big success compared with navigators, who enrolled less than 1% of total enrollees.
Another significant change was enhancement of the risk pool—CMS forced people to verify their qualification for Special Enrollment Periods, or SEPs, which caused a 56% decline in SEPs granted for the 2017 plan year.
The reports claim that enhancements to the federal exchange platforms helped maintain a steady effectuated enrollment rate for subsidized individuals who were moving into the 2018 plan year—a 3% growth was noted in effectuated enrollment by February 2018, compared with the same time last year. Enrollees on the exchanges rely on federal subsidies, the report shows; 87% enrolled in the 2018 plan year are dependent on Advance Premium Tax Credits—a 3% increase over the prior year.
Rising premiums on exchange plans exerted significant stress on the overall system and pushed federal spending on premium subsidies. Monthly premiums rose by 27% in 2018 following a 21% increase in 2017. Subsequently, the average federal premium subsidy rose by 39% in 2018, which is projected to increase federal spending on premium subsidies by $17 billion in this year.
The Exchange Trend Report, which delved into affordability, financial assistance, and plan choice for consumers on the Exchanges, found that lack of affordability remains a driving force that influences currently uninsured consumers’ decision to buy their healthcare coverage on the exchange through the federal platform.
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Pulmonary Hypertension Subtypes Show Distinct PA Flow Hemodynamics
March 21st 2025Investigators used 4D flow cardiovascular magnetic resonance imaging to search for differences between pulmonary artery (PA) remodeling in pulmonary arterial hypertension and other types of pulmonary hypertension.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
FDA Approves Vutrisiran to Mitigate Cardiomyopathy-Related Risks and Conditions
March 21st 2025In a recent decision, the FDA approved vutrisiran (amvuttra), making it the only approved therapy for adults with hereditary transthyretin-mediated amyloidosis (ATTR-CM) or wild-type cardiomyopathy.
Read More
Streamlining "Brain-to-Vein" Time, Patient Selection, Imperative for Implementing CAR T for MM
March 21st 2025Ajai Chari, MD, University of California San Francisco, explores the challenges that accompany integrating chimeric antigen receptor (CAR) T-cell therapies into multiple myeloma treatment.
Read More